Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$278.40 USD

278.40
1,732,273

-5.38 (-1.90%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $278.29 -0.11 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Reasons to Retain Prestige Consumer (PBH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.

Zacks Equity Research

CVS Health (CVS) Expands In-Home Diagnostic Care With New Test

by Zacks Equity Research

CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.

Zacks Equity Research

Here's Why You Should Add Ecolab (ECL) to Your Portfolio

by Zacks Equity Research

Ecolab's (ECL) focus on R&D raises optimism about the stock.

Zacks Equity Research

Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use

by Zacks Equity Research

Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.

Zacks Equity Research

BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease

by Zacks Equity Research

BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Zacks Equity Research

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Zacks Equity Research

Philips (PHG), SyntheticMR Unite to Aid Brain Diagnosing Space

by Zacks Equity Research

Philips (PHG) and SyntheticMR collaborate to launch of Smart Quant Neuro 3D, which is likely to boost the brain diagnosing field by providing automatic and precise 3D segmentation of brain tissues.

Zacks Equity Research

GE HealthCare's (GEHC) New Launch to Enhance Precision Care

by Zacks Equity Research

GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Equity Research

Centene (CNC), Pyx Health Unite to Treat Mental Health Issues

by Zacks Equity Research

Centene (CNC) partners with Pyx Health to address loneliness and mental health issues among the insured.

Zacks Equity Research

Philips' (PHG) CT 5300 to Boost Diagnostic Capabilities

by Zacks Equity Research

Philips (PHG) announces its latest innovation, Philips CT 5300, which leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities.

Zacks Equity Research

Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer

by Zacks Equity Research

Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.

Zacks Equity Research

Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact

by Zacks Equity Research

Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.

Zacks Equity Research

Veeva Systems (VEEV) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both segments.

Zacks Equity Research

Veradigm (MDRX) to Acquire AI Service Provider ScienceIO

by Zacks Equity Research

Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.

Zacks Equity Research

Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised

by Zacks Equity Research

Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.

Zacks Equity Research

Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down

by Zacks Equity Research

Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.

Zacks Equity Research

Integra's (IART) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.

Zacks Equity Research

National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.

Zacks Equity Research

Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw

by Zacks Equity Research

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Zacks Equity Research

Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.

Zacks Equity Research

Cencora (COR) Is Up 2.40% in One Week: What You Should Know

by Zacks Equity Research

Does Cencora (COR) have what it takes to be a top stock pick for momentum investors? Let's find out.